29.01.2010 • News

Ashland Looks Positively at 2010

Ashland CEO Jim O'Brien told shareholders at its annual meeting that its improved financial results are better than normal seasonality would indicate and that it had exceeded its cost-cutting goals through December. Cost savings on a continuing annual basis hit $405 million by year end, better than its $400 million target, he said.

The company earned $86 million, or $1.10 per share, in the first quarter of its 2010 fiscal year. That compared with a loss of $119 million, or $1.73 per share, in the same period a year earlier.

"If there is a negative on the horizon, it would be raw materials costs," O'Brien said.

Ashland's goal, he said, is to be in a global No. 1 or strong No. 2 position in each of the markets in which it operates.

Company

Logo:

Ashland

500 Hercules Road Building 8145
19808 Wilmington, DE
US

Company contact







From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

most read